Page 1

CareDx Reports First Quarter 2021 Results investors.caredxinc.com/news-releases/news-release-details/caredx-reports-first-quarter-2021-results Strong start to 2021 , raising full year guidance SOUTH SAN FRANCISCO , Calif . , May 05 , 2021 ( GLOBE NEWSWIRE ) -- Care Dx , Inc. ( Nasdaq : CDNA ) , a leading precision medicine company focused on the discovery , development , and commercialization of clinically differentiated , high - value healthcare solutions for transplant patients and caregivers , today reported financial results for the first quarter ended March 31 , 2021 . Recent Highlights : • Achieved total revenue of $ 67.4 million for the three months ended March 31 , 2021 , increasing 76 % year - over - year • Total AlloSure and AlloMap patient results provided in the quarter were approximately 33,200 , which includes approximately 5,900 AlloSure Heart patient results • As of March 31 , 2021 , over 60 U.S. - based transplant centers have adopted an AlloSure Kidney testing protocol , and we now connect more than 20,000 dialysis patients seeking to be referred for transplant with over 30 centers and greater than 500 dialysis centers through Tx Connect Completed successful public offering raising approximately $ 188.7 million in net proceeds , increasing cash , cash equivalents and marketable securities to $ 374.3 million as of March 31 , 2021 ● " Our record first quarter is a testament to the transplant focused , patient journey driven approach we have taken , as we deliver on our vision on being the leader in the transplant ecosystem , " said Reg Seeto , President and Chief Executive Officer of CareDx . " 2021 has started off strong because we continue to lead with innovation with our first and best in class offerings with AlloSure and AlloMap . Our strategy to bring multi - modality innovation and to connect the patient journey is working very well . " First Quarter 2021 Financial Results Revenue for the three months ended March 31 , 2021 was $ 67.4 million , an increase of 76 % compared with $ 38.4 million in the first quarter of 2020. Testing services revenue for the first quarter was $ 59.3 million , compared with $ 31.4 million in the same period of 2020. Product revenue in the three months ended March 31 , 2021 was $ 5.8 million , compared to $ 4.7 million in the same period of 2020. Digital and other revenue for the first quarter of 2021 was $ 2.3 million . For the first quarter of 2021 , net loss was $ 0.7 million compared to a net loss of $ 5.8 million in the same period of 2020. Basic and diluted net loss per share was $ 0.01 in the first quarter of 2021 , compared to basic and diluted net loss per share of $ 0.14 in the first quarter of 2020 . 1/9